Affiliation:
1. Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology, CHARUSAT-Campus,
Changa-388421, Anand, Gujarat, India
2. North Carolina State University, North Carolina, USA
Abstract
Abstract:
Cariprazine is a piperazine derivative approved by the USFDA in 2015 as a novel atypical
antipsychotic drug (APD) to treat adults with schizophrenia and bipolar manic or mixed episodes in
adults. However, due to the partial agonist action on dopamine D2, D3 receptors, and serotonin 5-HT1A
receptors as well as the antagonist effect on 5-HT2A, 5-HT2B, and H1 receptors, cariprazine differs
pharmacologically from other APDs, both typical and atypical. Moreover, cariprazine also has a
unique pharmacokinetic profile due to the formation of two clinically significant metabolites:
desmethyl-cariprazine (DCAR) and desmethyl-cariprazine (DDCAR). They are eliminated by
CYP3A4 and also, to a lesser extent, by CYP2D6. Here, we also review the effectiveness, safety, as
well as current clinical update of cariprazine in bipolar I disorder associated with/without mania and
schizophrenia through randomized and post-hoc analysis. The potential benefits of cariprazine as a
promising therapeutic alternative in addressing major clinical requirements for better therapy of such
severe neuropsychiatric conditions were demonstrated in this summarized review study.
Publisher
Bentham Science Publishers Ltd.
Subject
Pharmacology,General Neuroscience
Reference80 articles.
1. Diagnostic and statistical manual of mental disorders DSM-IV-TR American Psychiatric Association2000
2. Volavka J.; Citrome L.; Oral antipsychotics for the treatment of schizophrenia: Heterogeneity in efficacy and tolerability should drive decision-making. Expert Opin Pharmacother 2009,10(12),1917-1928
3. Mazza M.; Marano G.; Traversi G.; Carocci V.; Romano B.; Janiri L.; Cariprazine in bipolar depression and mania: State of the art. CNS Neurol Disord Drug Targets 2018,17(10),723-727
4. Amodeo G.; Fagiolini A.; Sachs G.; Erfurth A.; Older and newer strategies for the pharmacological management of agitation in patients with bipolar disorder or schizophrenia. CNS Neurol Disord Drug Targets 2017,16(8),885-890
5. Vazquez G.H.; Camino S.; Tondo L.; Baldessarini R.J.; Potential novel treatments for bipolar depression: Ketamine, fatty acids, anti-inflammatory agents, and probiotics. CNS Neurol Disord Drug Targets 2017,16(8),858-869
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献